97311 ⎘
Antibody mimetics or scaffolds Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
HER3 binding polypeptides
#302ENGINEERED PROTEINS INCLUDING MUTANT FIBRONECTIN DOMAINS
#303Anticalins
#304SYNBODIES TO AKT1
#305Stable liquid VEGF antagonist formulations
#306ALPHABODIES FOR HIV ENTRY INHIBITION
#307Artificial antibody polypeptides
#308Dimer VEGF antagonist formulations
#309Fibronectin based scaffold domain proteins that bind to PCSK9
#310STABILIZED IMMUNOGLOBULIN CONSTANT DOMAINS
#311Antigen-binding proteins
#312Synthetic Antibodies
#313Mixtures of binding proteins
#314Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#315Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#316SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS
#317Stabilized fibronectin domain compositions, methods and uses
#318SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#319Universal fibronectin type III binding-domain libraries
#320COMBINATION OF VEGFR2 AND IGF1R INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
#321Targeted therapeutics based on engineered proteins that bind EGFR
#322Fibronectin-based binding molecules and uses thereof
#323COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS
#324Universal fibronectin type III binding-domain libraries
#325Polypeptide derived from protein A and able to bind PDGF
#326ANTIGEN-BINDING CONSTRUCTS
#327Engineered antibody constant domain molecules
#328Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors
#329Non-natural proteinaceous scaffold made of three non-covalently associated peptides
#330Protein scaffolds
#331Anticalins
#332USE OF VEGFR-2 INHIBITORS FOR TREATING METASTATIC CANCER
#333VEGF antagonist formulations
#334IL-33 IN INFLAMMATORY DISEASE
#335COOPERATIVE AND DYNAMIC ASSEMBLY OF AFFINITY COMPLEXES
#336Ligand
#337Directed engagement of activating Fc receptors
#338Bispecific EGFR/IGFIR binding molecules
#339Universal fibronectin Type III binding-domain libraries
#340OB-FOLD USED AS SCAFFOLD FOR ENGINEERING NEW SPECIFIC BINDERS
#341Artificial antibody polypeptides
#342Multivalent fibronectin based scaffold domain proteins
#343SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#344Artificial antibody polypeptides
#345Ligand
#346Reconstituted polypeptides
#347TARGET RECOGNIZING BINDING AGENTS
#348Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
#349Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
#350Biokinetics of fast-clearing polypeptides
#351Universal fibronectin type III binding-domain libraries
#352ANTIGEN-BINDING CONSTRUCTS
#353Compositions and methods of producing hybrid antigen binding molecules and uses thereof
#354Plad Domain Peptides With Increased Serum Half Life Due To Conjugation To Domain Antibodies
#355AUTOPHILIC ANTIBODIES
#356Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
#357MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS
#358Trimeric collagen scaffold antibodies
#359Nucleic acids encoding polyvalent protein complexes
#360Pharmaceutically acceptable Fn3 Polypeptides for human treatments
#361Selection of fibronectin scaffolds using nucleic acid-protein fusions
#362Polypeptide
#363Fibronectin derivative Fc fusions
#364High affinity fibronectin derivatives
#365METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
#366RECOMBINANT TRIPLEX SCAFFOLD-BASED POLYPEPTIDES
#367Pharmacokinetic modulation and compositions for modified FN3 polypeptides
#368Inhibitors of type 2 vascular endothelial growth factor receptors
#369Ligand
#370Protein scaffolds for antibody mimics and other binding proteins
#371Mixture of binding proteins
#372Artificial antibody comprising complementary peptide
#373Pharmaceutical preparations of Fn3 polypeptides for human treatments
#374Artificial antibody polypeptides
#375Pharmaceutically acceptable FN3 polypeptides for human treatments
#376Artificial antibody polypeptides
#377Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
#378VEGF antagonist formulations
#379Ligand
#380Ligand
#381Anticalins
#382Variable domain library and uses
#383Protein scaffolds for antibody mimics and other binding proteins
#384High affinity fusion proteins and therapeutic and diagnostic methods for use
#385Protein scaffolds for antibody mimics and other binding proteins
#386High affinity fusion proteins and therapeutic and diagnostic methods for use
#387Polyvalent protein complex